Aura Biosciences, Inc. (NASDAQ:AURA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Aura Biosciences, Inc. (NASDAQ:AURA) has received a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $20.50.

A number of equities analysts have recently commented on the stock. Zacks Research raised shares of Aura Biosciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 19th. HC Wainwright restated a “buy” rating and set a $22.00 price objective on shares of Aura Biosciences in a report on Wednesday, August 13th. Evercore ISI assumed coverage on Aura Biosciences in a research note on Tuesday. They issued an “outperform” rating for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aura Biosciences in a research report on Monday.

Insider Transactions at Aura Biosciences

In other Aura Biosciences news, insider Janet Jill Hopkins sold 17,109 shares of the stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $5.42, for a total transaction of $92,730.78. Following the sale, the insider owned 252,685 shares of the company’s stock, valued at $1,369,552.70. This represents a 6.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CTO Mark Plavsic sold 12,169 shares of the company’s stock in a transaction that occurred on Thursday, October 16th. The stock was sold at an average price of $6.35, for a total transaction of $77,273.15. Following the transaction, the chief technology officer owned 197,287 shares in the company, valued at $1,252,772.45. The trade was a 5.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 39,223 shares of company stock valued at $233,155 in the last three months. 6.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of AURA. Tower Research Capital LLC TRC increased its stake in shares of Aura Biosciences by 49.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock valued at $40,000 after buying an additional 2,104 shares during the period. Water Island Capital LLC bought a new position in Aura Biosciences in the third quarter valued at about $64,000. 49 Wealth Management LLC acquired a new stake in Aura Biosciences in the third quarter worth about $66,000. Invesco Ltd. bought a new stake in Aura Biosciences during the 2nd quarter worth about $76,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Aura Biosciences by 24.3% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 12,453 shares of the company’s stock worth $78,000 after purchasing an additional 2,434 shares during the last quarter. Institutional investors and hedge funds own 96.75% of the company’s stock.

Aura Biosciences Trading Up 4.4%

Shares of NASDAQ:AURA opened at $6.38 on Friday. The stock has a market capitalization of $405.13 million, a PE ratio of -3.29 and a beta of 0.45. Aura Biosciences has a 1 year low of $4.34 and a 1 year high of $9.53. The firm has a fifty day moving average price of $5.90 and a 200 day moving average price of $6.23.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.06. On average, sell-side analysts forecast that Aura Biosciences will post -1.66 earnings per share for the current fiscal year.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.